NCT02705196 2026-02-24
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
Phase 1/2 Completed
Clinical Trials
84 trialsNCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT03697564 2025-08-06
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
University of California, San Diego
Phase 2 Completed
NCT04306900 2025-07-29
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT03884556 2025-07-02
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT05673811 2025-04-16
VIRAGE
Theriva Biologics SL
Phase 2 Completed
NCT02650804 2025-03-26
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
BPGbio
Phase 2 Completed
NCT00446225 2025-03-05
EURTAC
Spanish Lung Cancer Group
Phase 3 Completed
NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT03997968 2024-12-24
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Phase 1/2 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT03507491 2024-10-04
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Emory University
Phase 1 Completed
NCT03267316 2024-08-22
CANFOUR
Cantargia AB
Phase 1/2 Completed
NCT01231347 2024-07-16
GAMMA
NantCell, Inc.
Phase 3 Completed
NCT02352337 2024-07-10
PANOPTIMOX
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03434262 2024-05-31
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT00020345 2023-10-31
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT01964430 2023-06-28
apact
Celgene
Phase 3 Completed
NCT02210559 2023-03-02
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Kyntra Bio
Phase 1/2 Completed
NCT03665441 2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3 Completed
NCT03102320 2022-06-30
ARCS-Multi
Bayer
Phase 1 Completed
NCT02138383 2021-08-17
Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02045602 2020-10-08
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
Theriva Biologics SL
Phase 1 Completed
NCT02077881 2020-05-28
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
NCT03027284 2020-05-19
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03403049 2020-04-22
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Albert Einstein College of Medicine
Phase 1 Completed
NCT02559674 2020-01-27
QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
Altor BioScience
Phase 1 Completed
NCT02071537 2019-11-25
Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors
University of Cincinnati
Phase 1 Completed
NCT01088815 2019-04-26
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02900742 2019-04-12
Clinical Study of Chinese Medicine Plus Chemotherapy Maintenance in Advanced Non Small Cell Lung Cancer
Shanghai University of Traditional Chinese Medicine
Phase 3 Completed
NCT01453153 2018-11-30
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Halozyme Therapeutics
Phase 1/2 Completed
NCT01764828 2018-11-01
BAY86-9766 Plus Gemcitabine Phase I Study in Asian
Bayer
Phase 1 Completed
NCT01358968 2018-10-25
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
Eli Lilly and Company
Phase 1 Completed
NCT00557492 2018-09-25
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
University of Pittsburgh
Phase 2 Completed
NCT01663272 2018-09-19
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT02620423 2018-09-13
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
Phase 1 Completed
NCT02195180 2018-07-27
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
ERYtech Pharma
Phase 2 Completed
NCT00678132 2018-07-05
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00870870 2018-06-01
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Eli Lilly and Company
Phase 2 Completed
NCT01373164 2018-05-16
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT01342224 2018-04-12
Immunochemoradiotherapy in Patients With Pancreatic Cancer
Providence Health & Services
Phase 1 Completed
NCT01285037 2018-02-20
A Study of LY2801653 in Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01460537 2017-10-04
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer
Bayer
Phase 1 Completed
NCT01016483 2017-07-13
Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
EMD Serono
Phase 1/2 Completed
NCT01165905 2017-06-23
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
Traws Pharma, Inc.
Phase 1 Completed
NCT00061308 2017-06-09
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01447225 2016-09-14
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
Merrimack Pharmaceuticals
Phase 1 Completed
NCT00705874 2016-07-21
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Progen Pharmaceuticals
Phase 1 Completed